Neumora Therapeutics Inc. (NMRA)
NASDAQ: NMRAHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
NMRA stock chart
Technical analysisKey statistics
All statistics- Market cap
- $63.01M
- EPS (TTM)
- -$1.06
- Dividend yield
- None
- 52-week range
- 0.301 – 3.65
- Day range
- 0.3011 – 0.3599
- Volume / Avg
- 1.06M / 1.69M
- Beta
- —
- Shares outstanding
- 188.69M
52-week range
NMRA stock today
On Nov 20, NMRA ended the session at $0.3339, shedding $0.0131 (3.78%), versus the S&P 500's 3.70% decline. At this level, NMRA sits near the bottom of its 52-week range of $0.301 to $3.65: 90.9% below the high, set on Feb 18, 2026 and 10.9% above the low. NMRA is down 81.3% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 85.7%.
Neumora Therapeutics has posted a net loss over the last twelve months (EPS of -$1.06), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Neumora Therapeutics
Company profileNeumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in Phase 1b clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-861 and NMRA-898, a M4 muscarinic receptor positive allosteric modulators (PAMs) for schizophrenia and other neuropsychiatric disorders.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Dr. Joshua Pinto Ph.D.
- Headquarters
- Watertown, MA
- Employees
- 63
- IPO year
- 2023
- Website
- neumoratx.com
Financial highlights
Full financialsNeumora Therapeutics reported a net loss of $236.9 million, compared with a loss of $243.8 million a year earlier. Diluted earnings per share came in at -$1.45.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Growth | — | — | — | — |
| Net income | $-236.93M | $-243.79M | $-235.93M | $-130.90M |
| EPS (diluted) | $-1.45 | $-1.53 | $-3.63 | $-4.81 |
Analyst forecast
ForecastConsensus (9 analysts)
buy
Avg. price target
$6.00+1696.95%
- Strong buy 2
- Buy 5
- Hold 1
- Sell 0
- Strong sell 1
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 16, 2026
- EPS actual vs est.
- $-0.18 vs $-0.19
- Surprise
- +5.26%
NMRA news
All NMRA newsNeumora Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ATRAAtara Biotherapeutics Inc. | 6.33 | -0.16% | $64.49M | vs NMRA |
| TNYATenaya Therapeutics Inc. | 0.2866 | -3.99% | $65.32M | vs NMRA |
| CSBRChampions Oncology Inc. | 4.34 | -1.36% | $60.41M | vs NMRA |
| CRDFCardiff Oncology Inc. | 0.8528 | -4.46% | $66.34M | vs NMRA |
| CHRSCoherus Oncology Inc. | 0.3698 | -4.47% | $57.15M | vs NMRA |
| OKYOOKYO Pharma Limited | 1.07 | -7.76% | $56.15M | vs NMRA |
| CGTXCognition Therapeutics Inc. | 0.5822 | -3.06% | $55.37M | vs NMRA |
| AVXLAnavex Life Sciences Corp. | 0.5915 | -11.39% | $54.83M | vs NMRA |
Indexes, lists and sector
Neumora Therapeutics stock FAQ
What is Neumora Therapeutics's stock price today?
NMRA last traded at $0.3339 as of Nov 20, 4:00 PM EST, down 3.78% on the day. Prices are delayed at least 15 minutes.
Who is Neumora Therapeutics's CEO?
Dr. Joshua Pinto Ph.D. is the chief executive officer of Neumora Therapeutics Inc., which has about 63 employees.
What is the NMRA 52-week high?
The 52-week high for NMRA is $3.65 and the 52-week low is $0.301. The stock is currently 90.9% below its high.